La cadena de opciones muestra datos clave de las opciones de acciones de Vaccinex a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Vaccinex..

Vaccinex (OTC:VCNX) Bolsa, Cadena de Opciones

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

News

General

DKNG

DraftKings To Introduce Transaction Fee In Illinois; To Implement 50c Deal Fee On Illinois Bets

QNCX

Quince Therapeutics Reveals Pricing Of Up To $22M Private Placement Of Securities; Financing To Provide $11.5M Upfront, $10.4M From Warrants; Proceeds To Fund Phase 3 Neat Trial And Corporate Purposes

BJ's Wholesale Club Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) has outperformed the market over the past 5 years by 11.42% on an annualized basis producing an average annual return of 25.47%. Currently, BJ's Wholesale Club Hldgs has a market capitalization of $14.48 billion. 
Buying $1000 In BJ: If an investor had bought $1000 of BJ stock 5 years ago, it would be worth $3,237.67 today based on a price of $109.66 for BJ at the time of writing.
<h3>BJ's Wholesale Club Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749762911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In BJ's Wholesale Club Hldgs 5 Years Ago Would Be Worth Today

While the wider business community awaited news regarding <a href="https://www.benzinga.com/news/macro-notification/25/06/45876366/howard-lutnick-says-us-and-china-reached-a-framework-to-implement-geneva-consensus-following-trump-xi-call-csi-300-index-gains">trade negotiations</a> between the U.S. and China, one of the more anxious names may have been Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>). As a semiconductor equipment specialist, Applied Materials represents a vital cog for multiple tech sectors, including computers, smartphones and solar products. However, tensions between the world's top two economies threatened the company's access to critical rare earth minerals.
To be sure, the immediate response to the new trade deal framework — announced on Tuesday following two days of high-level discussions between U.S. and Chinese officials — was muted. While analysts in principle are encouraged by the agreement, which involves both sides rolling back contentious actions, it is <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45900295/this-is-another-band-aid-say-experts-questioning-long-term-viability-and-efficacy-of-us-china-trade-deal-china-always-had-this-trump-card">still pending approval</a> from President Donald Trump and Chinese counterpart Xi Jinping.
Derek Scissors, a senior fellow at the American Enterprise Institute, remarked that the deal is merely another "band aid." He further warned that China could easily reinstate the blockade on rare earths. Marc Busch, a professor of international business diplomacy at Georgetown University, added to the concerns, noting that China's rhetoric hasn't shifted, raising doubts regarding the sustainability of negotiations.
Despite the headwinds, the broader point is that the Trump administration, for all its tough talk, likely understands the consequences of unmitigated aggression. The president has previously <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45715677/tom-lee-bets-on-a-new-bull-market-as-trumps-tariff-retreat-fuels-taco-trade-amid-run-it-hot-optimism">issued stern warnings and later walked back</a> the magnitude of his policies. China being the world's second-largest economy, the White House can't afford to act imprudently.
On the other end, the Chinese economy isn't all rainbows and gummy bears either. When tensions first erupted, China was already dealing with serious issues, such as <a href="https://www.benzinga.com/markets/25/04/45033463/as-china-downplays-trump-tariffs-with-5-growth-target-top-economist-warns-of-90-chance-of-a-us-recession-amid-trade-war">deflation and a prolonged property crisis</a>. Both sides have reason to play ball and that ultimately may be good news for Applied Materials.
<h2 class="wp-block-heading">Statistical Backdrop Smiles Favorably On AMAT Stock</h2>
While narratives provide the context and color surrounding a particular asset or enterprise, they're not great at forecasting market behaviors. Storylines focus on the "why" of an investment. But when it comes to trading, participants of this discipline tend to focus on the "how" — how much, how fast and most importantly, how likely.
With options trading in particular, it's not enough to have confidence that AMAT stock will move in a certain direction. Depending on the specific strategy, the magnitude of movement is critical. At the same time, all options expire. Therefore, the speculated move must occur within the defined window. This makes probability the centerpiece of options market analysis.
Tackling the topic of probabilities isn't easy using traditional methodologies of fundamental and technical analysis. That's because both approaches suffer from the non-stationarity dilemma: the metric of comparison (such as share price or earnings) fluctuates temporally and contextually. Also, pattern-based technical analysis — while offering a visual representation of price behaviors — is not falsifiable.
To remedy this problem, traders can impose stationarity by converting pricing data into market breadth sequences; that is, sequences of accumulative and distributive sessions. Doing so creates a binary ecosystem, where demand profiles are assessed by a simple observation — it's either happening or it's not.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12151610/AMAT-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-948180" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12151610/AMAT-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12151610/AMAT-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12151610/AMAT-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12151610/AMAT-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Currently, AMAT stock is on course to print a "6-4-U" sequence: six up weeks, four down weeks, with a net positive trajectory across the 10-week period. In 56.67% of cases, the following week's price action results in upside, with a median return of 2.26%. Assuming that AMAT closes this Friday at $175, it could potentially rise to just under $179 in short order, perhaps a week or two.
Should the bulls maintain control of the market, historical trends suggest that AMAT stock could push toward the $181 level in the next three to four weeks.
<h2 class="wp-block-heading">An Optimistic But Sensible Trade For Applied Materials</h2>
Based on the market intelligence above, the multi-leg options strategy that arguably stands out the most is the 177.50/180 bull call spread expiring July 11. This transaction involves buying the $177.50 call and simultaneously selling the $180 call, for a net debit paid of $125. Should AMAT stock rise through the short strike price ($180) at expiration, the maximum reward is also $125, a payout of 100%.
Primarily, this trade is attractive because of the statistical response to the 6-4-U sequence. With the fundamentals also aligning positively, AMAT stock in theory should have enough fuel to trigger the short strike price at expiration.
Further, the 6-4-U represents a positive uptick in terms of sentiment regime. As a baseline, the chance that a long position will be profitable over any given week is 54%. With the aforementioned sequence, the bullish trader receives almost 3 percentage points of favorable odds.
Granted, it's not the biggest advantage. However, the advantage is still on the bulls' side, incentivizing a long-side debit strategy. As well, the political backdrop adds credibility to the argument.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/06/45893665/mrvl-stock-trade-agreement-sleeper-options-opportunity">Options Corner: Why The Latest U.S.-China Trade Agreement Makes Marvell A Sleeper Opportunity</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

AMAT

Options Corner: Diplomatic Progress Clears The Path For This Call Spread On Applied Materials

<a href="https://trumpstruth.org/statuses/31488">https://trumpstruth.org/statuses/31488</a>

President Trump Says We Remain Committed To A Diplomatic Resolution To Iran Nuclear Issue; My Entire Administration Has Been Directed To Negotiate With Iran; Iran First Must Completely Give Up Hopes Of Obtaining A Nuclear Weapon

Management

ONTO

Onto Innovation Appoints Brian Roberts As CFO, Effective As Of June 16, 2025

<a href="https://www.reuters.com/business/aerospace-defense/after-trump-feud-role-musks-spacex-golden-dome-missile-shield-question-2025-06-12/">https://www.reuters.com/business/aerospace-defense/after-trump-feud-role-musks-spacex-golden-dome-missile-shield-question-2025-06-12/</a>

'After Trump feud, role of Musk's SpaceX in Golden Dome missile shield in question'- Reuters Exclusive

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 8.5% to $1.15 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock rose 7.1% to $8.59. The market value of their outstanding shares is at $104.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.07% to $0.26. The company's market cap stands at $69.7 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) stock moved upwards by 6.58% to $5.5. The market value of their outstanding shares is at $30.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.91% to $0.33. The company's market cap stands at $1.4 million. </li>
<li>Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) stock increased by 5.52% to $4.2. The company's market cap stands at $292.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 16.3% to $0.03 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) shares declined by 12.7% to $1.72. The market value of their outstanding shares is at $38.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares decreased by 10.79% to $18.12. The company's market cap stands at $471.3 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 8.63% to $0.28. The market value of their outstanding shares is at $7.5 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock decreased by 8.19% to $4.15. The market value of their outstanding shares is at $388.2 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 6.52% to $0.14. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

BIAF

CMPS

HCAT

HCTI

LIMN

NCNA

NUWE

PLRZ

RNTX

SCLX

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) shares increased by 6.3% to $7.7 during Thursday's after-market session. The company's market cap stands at $11.0 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares increased by 6.14% to $0.2. The company's market cap stands at $5.9 million. </li>
<li>CEA Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) shares moved upwards by 5.99% to $10.6. The market value of their outstanding shares is at $8.5 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock moved upwards by 5.02% to $0.36. The market value of their outstanding shares is at $4.5 million. </li>
<li>Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) stock increased by 4.94% to $2.76. The company's market cap stands at $321.8 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock rose 4.73% to $0.57. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares declined by 12.9% to $0.08 during Thursday's after-market session. The market value of their outstanding shares is at $11.0 million. </li>
<li>Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares decreased by 4.9% to $7.19. The market value of their outstanding shares is at $194.6 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock decreased by 4.88% to $0.27. The market value of their outstanding shares is at $9.0 million. </li>
<li>INLIF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INLF#NASDAQ">INLF</a>) stock decreased by 4.4% to $0.87. The market value of their outstanding shares is at $13.8 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) stock declined by 4.18% to $2.07. The company's market cap stands at $3.9 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares decreased by 3.86% to $3.24. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CIGL

INLF

LNKS

LVRO

RYDE

SOAR

UGRO

12 Industrials Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) shares rose 15.8% to $2.12 during Thursday's after-market session. The company's market cap stands at $45.4 million. </li>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) shares rose 8.66% to $7.15. The market value of their outstanding shares is at $7.8 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares moved upwards by 6.15% to $5.35. The company's market cap stands at $33.6 million. </li>
<li>One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) shares moved upwards by 6.14% to $3.63. The market value of their outstanding shares is at $78.3 million. </li>
<li>CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) stock increased by 5.3% to $2.78. The market value of their outstanding shares is at $40.3 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares increased by 4.99% to $4.41. The market value of their outstanding shares is at $10.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) stock fell 5.7% to $2.3 during Thursday's after-market session. The market value of their outstanding shares is at $17.2 million. </li>
<li>BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) stock declined by 5.53% to $2.05. The company's market cap stands at $32.7 million. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares fell 5.32% to $0.23. The market value of their outstanding shares is at $1.5 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares decreased by 5.22% to $0.93. The market value of their outstanding shares is at $18.0 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares decreased by 4.66% to $2.46. The market value of their outstanding shares is at $30.8 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) shares decreased by 4.21% to $1.14. The market value of their outstanding shares is at $181.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

BTCM

CGTL

CPSH

FORD

FOXO

Nuveen California Dividend Advantage Municipal Fund 2

SAGT

SMSI

XTIA

12 Information Technology Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) shares rose 10.2% to $0.71 during Thursday's after-market session. The market value of their outstanding shares is at $15.1 million. </li>
<li>TMD Energy Limited Ordinary Shares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#AMEX">TMDE</a>) shares moved upwards by 5.52% to $0.79. </li>
<li>Aemetis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) stock rose 5.26% to $2.0. The market value of their outstanding shares is at $110.7 million. </li>
<li>Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) shares rose 4.94% to $4.88. The market value of their outstanding shares is at $319.1 million. </li>
<li>Crown LNG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock moved upwards by 3.97% to $0.09. The company's market cap stands at $39.8 million. </li>
<li>MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) shares rose 3.64% to $6.26. The company's market cap stands at $49.8 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>New Era Helium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) shares declined by 7.7% to $0.56 during Thursday's after-market session. The company's market cap stands at $8.0 million. </li>
<li>Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) stock fell 7.23% to $18.75. The company's market cap stands at $1.1 billion. </li>
<li>Houston American Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#AMEX">HUSA</a>) shares fell 4.35% to $6.83. The market value of their outstanding shares is at $10.7 million. </li>
<li>Barnwell Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BRN#AMEX">BRN</a>) stock fell 4.35% to $1.32. The company's market cap stands at $13.2 million. </li>
<li>PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) stock decreased by 3.75% to $20.05. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Heidmar Maritime Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) shares fell 3.3% to $1.76. The market value of their outstanding shares is at $102.3 million. As per the press release, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-energy-stocks/" title="www.benzinga.com/money/best-energy-stocks/">www.benzinga.com/money/best-energy-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMTX

CGBS

GPRE

HUSA

MIND

NEHC

SKYQ

TMDE

12 Energy Stocks Moving In Thursday's After-Market Session

Buybacks

FLOC

Flowco Holdings Announces $50M Stock Repurchase Program

PPIH

Perma-Pipe International CEO David Mansfield Departs; Saleh Sagr Appointed As President And CEO, Effectively Immediately

In the current market session, The Hartford Insurance Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) share price is at $126.26, after a 1.52% increase. Moreover, over the past month, the stock fell by 2.31%, but in the past year, increased by 26.93%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1749762022_0.png" alt="Past Year Chart" />

<h3>The Hartford Insurance Gr P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
The Hartford Insurance Gr has a lower P/E than the aggregate P/E of 23.58 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749762022_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into The Hartford Insurance Gr Inc's Price Over Earnings

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) has outperformed the market over the past 5 years by 7.08% on an annualized basis producing an average annual return of 21.12%. Currently, Corteva has a market capitalization of $49.47 billion. 
Buying $1000 In CTVA: If an investor had bought $1000 of CTVA stock 5 years ago, it would be worth $2,709.00 today based on a price of $72.52 for CTVA at the time of writing.
<h3>Corteva's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749762015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

Here's How Much $1000 Invested In Corteva 5 Years Ago Would Be Worth Today

<a href="https://www.bloomberg.com/news/articles/2025-06-12/apple-targets-spring-2026-for-release-of-delayed-siri-ai-upgrade?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-12/apple-targets-spring-2026-for-release-of-delayed-siri-ai-upgrade?embedded-checkout=true</a>

AAPL

'Apple Targets Spring 2026 for Release of Delayed Siri AI Upgrade'- Bloomberg

FCPT

Four Corners Property Trust Acquires An Automotive Service Property Leased To A National Operator For $5.8M

Merck Animal Health, A Division Of Merck & Co,  Receives Positive Opinion For NUMELVI Tablets For Dogs From European Medicines Agency's Committee

RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) reported first-quarter financial results after the market close on Thursday that included a surprise earnings beat, <a href="https://www.benzinga.com/pressreleases/25/06/b45914093/rh-reports-first-quarter-fiscal-2025-results">sending shares higher</a>. 
Q1 Earnings: RH reported first-quarter revenue of $813.95 million, missing the <a href="https://www.benzinga.com/quote/RH/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $818.12 million, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The luxury retailer reported first-quarter adjusted earnings of 13 cents per share, surpassing analyst estimates calling for a loss of nine cents per share.
Total revenue was up 12% on a year-over-year basis despite the &#8220;polarizing impact&#8221; of tariff uncertainty and &#8220;the worst housing market in almost 50 years.&#8221; RH noted its substantial investments aimed at elevating and expanding the company&#8217;s product and platform resulted in significant share gains and strategic separation.
&#8220;While we expect a higher risk business environment this year due to the uncertainty caused by tariffs, market volatility, inflation risk, and an increasing level of global discord, we believe it's important to separate the signal from the noise,&#8221; the company said in a letter to shareholders.
&#8220;Despite that fact, we are performing at a level most would expect in a robust housing market.&#8221;
Outlook: RH anticipates second-quarter revenue growth of 8% to 10%, and full-year 2025 revenue growth of 10% to 13%.
RH expects to generate $250 to $350 million of free cash flow in 2025. The company estimated that its adjusted capital expenditures will decrease to a range of $200 million to $250 million in 2026, and $150 to $200 million in 2027 and beyond.
&#8220;Due to the significant and unexpected Liberation Day Tariffs announced on April 2nd, shipments and resourcing efforts were disrupted globally. We believe the disruption will negatively impact revenues by approximately 6 points in the second quarter and will be recovered in the second half, which is reflected in our outlook,&#8221; the company said.
RH&#8217;s management team will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
RH Price Action:&nbsp;<a href="http://benzinga.com/quote/rh" target="_blank" rel="noreferrer noopener">RH shares</a>&nbsp;were up 19.41% in after-hours, trading at $211.20 at the time of publication on Thursday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/06/45913847/the-dollar-is-crumbling-and-hedge-fund-analyst-says-a-new-global-trade-is-brewing">The Dollar Is Crumbling, And Hedge Fund Analyst Says A New Global Trade Is Brewing</a></li>
</ul>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45914913/mp-materials-stock-surges-on-report-of-us-government-funding-for-rare-earths">MP Materials Stock Surges On Report Of US Government Funding For Rare Earths</a></li>
</ul>
Photo: Shutterstock.

Earnings

Guidance

After-Hours Center

RH Stock Surges On Q1 Earnings Beat Despite 'Worst Housing Market' In 50 Years

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 10 years by 7.41% on an annualized basis producing an average annual return of 18.52%. Currently, Welltower has a market capitalization of $98.50 billion. 
Buying $100 In WELL: If an investor had bought $100 of WELL stock 10 years ago, it would be worth $549.40 today based on a price of $151.91 for WELL at the time of writing.
<h3>Welltower's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749761111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WELL

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Financing

Press Releases

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Health Care

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNX

Comments

Vaccinex

Vaccinex (VCNX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL